BioMarin Pharmaceutical (BMRN) Revenue & Revenue Breakdown
BioMarin Pharmaceutical Revenue Highlights
Latest Revenue (Y)
$2.42B
Latest Revenue (Q)
$712.03M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
BioMarin Pharmaceutical Revenue by Period
BioMarin Pharmaceutical Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.42B | 15.42% |
| 2022-12-31 | $2.10B | 13.53% |
| 2021-12-31 | $1.85B | -0.76% |
| 2020-12-31 | $1.86B | 9.18% |
| 2019-12-31 | $1.70B | 14.27% |
| 2018-12-31 | $1.49B | 13.52% |
| 2017-12-31 | $1.31B | 17.62% |
| 2016-12-31 | $1.12B | 25.50% |
| 2015-12-31 | $889.89M | 18.49% |
| 2014-12-31 | $751.04M | 36.93% |
| 2013-12-31 | $548.49M | 9.54% |
| 2012-12-31 | $500.72M | 13.45% |
| 2011-12-31 | $441.36M | 17.30% |
| 2010-12-31 | $376.27M | 15.90% |
| 2009-12-31 | $324.66M | 9.50% |
| 2008-12-31 | $296.49M | 143.86% |
| 2007-12-31 | $121.58M | 44.38% |
| 2006-12-31 | $84.21M | 228.06% |
| 2005-12-31 | $25.67M | 37.70% |
| 2004-12-31 | $18.64M | 54.06% |
| 2003-12-31 | $12.10M | -13.07% |
| 2002-12-31 | $13.92M | 18.98% |
| 2001-12-31 | $11.70M | -5.09% |
| 2000-12-31 | $12.33M | 76.69% |
| 1999-12-31 | $6.98M | 481.33% |
| 1998-12-31 | $1.20M | - |
BioMarin Pharmaceutical generated $2.42B in revenue during NA 2023, up 15.42% compared to the previous quarter, and up 162.23% compared to the same period a year ago.
BioMarin Pharmaceutical Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $712.03M | 9.74% |
| 2024-03-31 | $648.83M | 0.41% |
| 2023-12-31 | $646.21M | 10.28% |
| 2023-09-30 | $585.97M | -1.45% |
| 2023-06-30 | $594.60M | 0.28% |
| 2023-03-31 | $592.95M | 10.31% |
| 2022-12-31 | $537.54M | 6.37% |
| 2022-09-30 | $505.34M | -5.33% |
| 2022-06-30 | $533.80M | 2.78% |
| 2022-03-31 | $519.36M | 15.46% |
| 2021-12-31 | $449.81M | 10.05% |
| 2021-09-30 | $408.74M | -18.53% |
| 2021-06-30 | $501.69M | 3.22% |
| 2021-03-31 | $486.03M | 7.50% |
| 2020-12-31 | $452.12M | -5.17% |
| 2020-09-30 | $476.78M | 11.01% |
| 2020-06-30 | $429.49M | -14.46% |
| 2020-03-31 | $502.07M | 10.48% |
| 2019-12-31 | $454.44M | -1.44% |
| 2019-09-30 | $461.10M | 18.91% |
| 2019-06-30 | $387.76M | -3.24% |
| 2019-03-31 | $400.75M | 13.46% |
| 2018-12-31 | $353.21M | -9.83% |
| 2018-09-30 | $391.71M | 5.06% |
| 2018-06-30 | $372.85M | -0.16% |
| 2018-03-31 | $373.45M | 4.23% |
| 2017-12-31 | $358.31M | 7.23% |
| 2017-09-30 | $334.15M | 5.26% |
| 2017-06-30 | $317.45M | 4.51% |
| 2017-03-31 | $303.75M | 1.22% |
| 2016-12-31 | $300.09M | 7.22% |
| 2016-09-30 | $279.90M | -6.74% |
| 2016-06-30 | $300.13M | 26.78% |
| 2016-03-31 | $236.74M | 3.86% |
| 2015-12-31 | $227.94M | 9.11% |
| 2015-09-30 | $208.90M | -16.61% |
| 2015-06-30 | $250.52M | 23.25% |
| 2015-03-31 | $203.26M | -11.95% |
| 2014-12-31 | $230.85M | 30.54% |
| 2014-09-30 | $176.85M | -7.79% |
| 2014-06-30 | $191.79M | 26.55% |
| 2014-03-31 | $151.55M | 3.19% |
| 2013-12-31 | $146.87M | 7.31% |
| 2013-09-30 | $136.87M | 0.05% |
| 2013-06-30 | $136.81M | 6.94% |
| 2013-03-31 | $127.93M | -3.04% |
| 2012-12-31 | $131.94M | 2.98% |
| 2012-09-30 | $128.12M | 3.30% |
| 2012-06-30 | $124.02M | 6.32% |
| 2012-03-31 | $116.65M | 8.16% |
| 2011-12-31 | $107.85M | -4.92% |
| 2011-09-30 | $113.42M | 2.53% |
| 2011-06-30 | $110.63M | 1.07% |
| 2011-03-31 | $109.46M | 7.72% |
| 2010-12-31 | $101.61M | 3.95% |
| 2010-09-30 | $97.75M | 6.31% |
| 2010-06-30 | $91.95M | 8.24% |
| 2010-03-31 | $84.95M | -2.44% |
| 2009-12-31 | $87.08M | 7.77% |
| 2009-09-30 | $80.81M | -2.39% |
| 2009-06-30 | $82.79M | 11.90% |
| 2009-03-31 | $73.98M | -25.48% |
| 2008-12-31 | $99.28M | 36.66% |
| 2008-09-30 | $72.65M | 13.20% |
| 2008-06-30 | $64.17M | 6.26% |
| 2008-03-31 | $60.40M | 34.65% |
| 2007-12-31 | $44.85M | - |
BioMarin Pharmaceutical generated $712.03M in revenue during Q2 2024, up 9.74% compared to the previous quarter, and up 120.08% compared to the same period a year ago.
BioMarin Pharmaceutical Revenue Breakdown
BioMarin Pharmaceutical Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $2.37B | $2.04B | $1.78B | - | - |
| Royalty And Other | $46.69M | $54.01M | $62.78M | $54.59M | $43.01M |
| Enzyme Product | $1.72B | - | - | - | - |
| Product Two | - | - | - | - | $374.33M |
| Product Three | - | - | - | - | $463.35M |
| Product Six | - | - | - | - | $72.00M |
| Product Seven | - | - | - | - | $86.86M |
| Product Four | - | - | - | - | $544.35M |
| Product Five | - | - | - | - | $22.35M |
BioMarin Pharmaceutical's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (57.34%), Enzyme Product (41.53%), and Royalty And Other (1.13%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $702.13M | $637.82M | $633.15M | $568.27M | $584.70M | $586.43M | $525.49M | $493.35M | $517.66M | $505.52M | $435.22M | $393.84M | $486.67M | $437.05M | $436.58M | - | - | - | - | - |
| Royalty And Other | $9.90M | $11.02M | $13.06M | $13.06M | $10.58M | $9.99M | $12.05M | $12.00M | $16.14M | $13.83M | $14.59M | $14.90M | $15.02M | $18.26M | $15.07M | $16.04M | $10.45M | $13.03M | $17.86M | $10.20M |
| Enzyme Product | - | - | $448.03M | $401.52M | $420.74M | $448.11M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product Five | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.09M | $5.67M |
| Product Four | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $132.39M | $163.47M |
| Product Seven | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $31.61M | $24.14M |
| Product Six | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $25.18M | $19.84M |
| Product Three | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $122.58M | $120.52M |
| Product Two | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $94.87M | $94.41M |
BioMarin Pharmaceutical's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (98.61%), and Royalty And Other (1.39%).
BioMarin Pharmaceutical Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| UNITED STATES | $912.38M | $778.44M | $696.79M |
| Rest Of World | $223.75M | $197.63M | $172.94M |
| Latin America | $205.86M | $218.79M | $185.05M |
| Europe | $518.47M | $509.19M | $436.43M |
BioMarin Pharmaceutical's latest annual revenue breakdown by geography, as of Dec 20: UNITED STATES (49.04%), Europe (27.87%), Rest Of World (12.03%), and Latin America (11.07%).
Quarterly Revenue by Country
| Country | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Latin America | $38.96M | $42.25M | $59.70M | $64.01M | $44.06M | $37.86M | $59.92M | $54.66M | $83.80M | $46.49M | $33.84M | $33.09M | $55.32M | $58.16M | $27.77M |
| Europe | $115.50M | $172.68M | $161.84M | $143.01M | $121.16M | $109.26M | $145.04M | $139.60M | $125.48M | $119.56M | $124.54M | $112.49M | $111.07M | $107.22M | $68.80M |
| Rest Of World | $58.05M | $82.52M | $56.30M | $62.39M | $58.61M | $49.81M | $52.94M | $43.96M | $49.94M | $52.30M | $51.43M | $38.92M | $50.59M | $44.68M | $82.33M |
| UNITED STATES | $196.24M | $204.25M | $208.19M | $182.70M | $252.95M | $232.55M | $244.17M | $216.22M | $201.87M | $169.41M | $190.94M | $168.71M | $174.72M | $162.79M | $124.14M |
BioMarin Pharmaceutical's latest quarterly revenue breakdown by geography, as of Sep 21: UNITED STATES (48.01%), Europe (28.26%), Rest Of World (14.20%), and Latin America (9.53%).
BioMarin Pharmaceutical Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $1.04B |
| BMRN | BioMarin Pharmaceutical | $2.42B | $712.03M |
| EXEL | Exelixis | $1.83B | $637.18M |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $659.83M |
| TECH | Bio-Techne | $1.16B | $303.43M |
| HALO | Halozyme Therapeutics | $829.25M | $231.35M |
| IONS | Ionis Pharmaceuticals | $787.65M | $225.00M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| ARWR | Arrowhead Pharmaceuticals | $240.74M | - |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.62M |
| LQDA | Liquidia | $17.49M | $2.97M |
| MREO | Mereo BioPharma Group | $10.00M | - |
| KRTX | Karuna Therapeutics | $654.00K | - |
| PCVX | Vaxcyte | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
BMRN Revenue FAQ
What is BioMarin Pharmaceutical’s yearly revenue?
BioMarin Pharmaceutical's yearly revenue for 2023 was $2.42B, representing an increase of 15.42% compared to 2022. The company's yearly revenue for 2022 was $2.1B, representing an increase of 13.53% compared to 2021. BMRN's yearly revenue for 2021 was $1.85B, representing a decrease of -0.76% compared to 2020.
What is BioMarin Pharmaceutical’s quarterly revenue?
BioMarin Pharmaceutical's quarterly revenue for Q2 2024 was $712.03M, a 9.74% increase from the previous quarter (Q1 2024), and a 19.75% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $648.83M, a 0.41% increase from the previous quarter (Q4 2023), and a 9.43% increase year-over-year (Q1 2023). BMRN's quarterly revenue for Q4 2023 was $646.21M, a 10.28% increase from the previous quarter (Q3 2023), and a 20.22% increase year-over-year (Q4 2022).
What is BioMarin Pharmaceutical’s revenue growth rate?
BioMarin Pharmaceutical's revenue growth rate for the last 3 years (2021-2023) was 31.03%, and for the last 5 years (2019-2023) was 41.97%.
What are BioMarin Pharmaceutical’s revenue streams?
BioMarin Pharmaceutical's revenue streams in c 23 are Product, Royalty And Other, and Enzyme Product. Product generated $2.37B in revenue, accounting 57.34% of the company's total revenue, up 16.19% year-over-year. Royalty And Other generated $46.69M in revenue, accounting 1.13% of the company's total revenue, down -13.56% year-over-year. Enzyme Product generated $1.72B in revenue, accounting 41.53% of the company's total revenue
What is BioMarin Pharmaceutical’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of BioMarin Pharmaceutical was Product. This segment made a revenue of $2.37B, representing 57.34% of the company's total revenue.